Pall Corporation And SOTAX Deliver Cost-Effective Automation Certified Solutions For Automated Pharmaceutical Testing Systems

CORRECTING and REPLACING Pall Corporation And SOTAX Deliver Cost-Effective Automation Certified Solutions For Automated Pharmaceutical Testing Systems
Press Release  Print 

PORT WASHINGTON, N.Y., March 22, 2010 - The 4th graph, last sentence of release dated March 18, 2010 should be attributed to: Gilles Devidts (sted Gilles Devidtes).

The corrected release reads:

PALL CORPORATION AND SOTAX DELIVER COST-EFFECTIVE AUTOMATION CERTIFIED SOLUTIONS FOR AUTOMATED PHARMACEUTICAL TESTING SYSTEMS

Pall Corporation, (NYSE: PLL), a global leader in filtration, separation and purification, has announced a long-term joint marketing agreement with SOTAX Group that will include Pall Acrodisc® PSF syringe filters in all SOTAX dissolution systems for solid dosage forms. The exclusive agreement is the initial step that allows the companies to begin delivering complete certification solutions that save time and testing costs for quality control laboratories.

Pall Acrodisc PSF syringe filters are used by research and analytical laboratories to help expedite automated sample processing. First introduced in 1973, Pall's Acrodisc syringe filters provide improved retention efficiency to help extend HPLC column life by as much as 46 times. The multi-layered prefilter provides two to four times the throughput of standard glass fiber prefilter devices to allow for quick and easy filtration of samples that are difficult to filter. The PSF housing has been designed for smooth operation in automated systems and operating pressures, eliminating filter burst.

SOTAX is a Swiss-based provider of high-quality dissolution testing systems, composite assay and content uniformity workstations along with physical tablet testing instruments for the pharmaceutical industry. Dissolution testing is used by the pharmaceutical industry to characterize the dissolution properties of an active drug, an active drug's release and the dissolution from a dosage formulation. SOTAX systems formulate the drug dosage form and develop quality control specifications for the manufacturing process.

"By exclusively recommending Pall Acrodisc PSF technology as part of our testing systems, we can ensure we are providing the pharmaceutical industry with a significantly improved automated dissolution process for multiple unattended tests. This includes applications for media preparation and delivery, automated dosage introduction, automated sampling, filtering and sample analysis," said Gilles Devidts, Head of Product Management, SOTAX.

At the start of this agreement, all new SOTAX AT 70smart Dissolution systems and SOTAX CTS Content Uniformity test systems will include the Pall Acrodisc PSF syringe filters. Filter refills will be available directly from Pall Life Sciences through its regular sales and distribution channel.

"This marketing partnership with SOTAX advances the performance of the automated laboratory analysis platform," said Larry O'Connell, Senior Vice President, Global Lab Products for Pall Life Sciences. "Customers can now obtain the dual benefits associated with SOTAX and Pall technology to achieve superior analysis and performance."

To learn more about Acrodisc PSF syringe filters, visit www.pall.com/lab.

To order, call 1-800-521-1520 in the U.S./Canada or (+)800-PALL-LIFE in all other locations. E-mail Pall Life Sciences at [email protected]

Pall Life Sciences

Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall technologies are also used to collect and process blood components and help protect patients from hospital-acquired infections. The company's membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing Total Fluid ManagementSM solutions to meet the critical needs of customers in biopharmaceutical; hospital, transfusion and veterinary medicine; energy and alternative energy; electronics; municipal and industrial water; aerospace; transportation and broad industrial markets. Together with our customers, we foster health, safety and environmentally responsible technologies. The Company's engineered solutions enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.3 billion for fiscal 2009, is a S&P 500 company with more than 10,000 employees servicing customers worldwide. Pall has been named a top "green company" by Newsweek magazine. To see how Pall is helping enable a greener and more sustainable future, visit www.pall.com.

Note to Editors: A high-resolution photograph of the Acrodisc PSF syringe filter is available for download at www.pall.com/news

www.pall.com/lab

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6220206&lang=en

 


Contact:
Pall Life Sciences
Carol Flint - VP Marketing Communications
Phone: 734-913-6432
 

 

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.